2022
Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
Korenblik R, Olij B, Aldrighetti LA, Hilal MA, Ahle M, Arslan B, van Baardewijk LJ, Baclija I, Bent C, Bertrand CL, Björnsson B, de Boer MT, de Boer SW, Bokkers RPH, Rinkes IHMB, Breitenstein S, Bruijnen RCG, Bruners P, Büchler MW, Camacho JC, Cappelli A, Carling U, Chan BKY, Chang DH, choi J, Font JC, Crawford M, Croagh D, Cugat E, Davis R, De Boo DW, De Cobelli F, De Wispelaere JF, van Delden OM, Delle M, Detry O, Díaz-Nieto R, Dili A, Erdmann JI, Fisher O, Fondevila C, Fretland Å, Borobia FG, Gelabert A, Gérard L, Giuliante F, Gobardhan PD, Gómez F, Grünberger T, Grünhagen DJ, Guitart J, Hagendoorn J, Heil J, Heise D, Herrero E, Hess GF, Hoffmann MH, Iezzi R, Imani F, Nguyen J, Jovine E, Kalff JC, Kazemier G, Kingham TP, Kleeff J, Kollmar O, Leclercq WKG, Ben SL, Lucidi V, MacDonald A, Madoff DC, Manekeller S, Martel G, Mehrabi A, Mehrzad H, Meijerink MR, Menon K, Metrakos P, Meyer C, Moelker A, Modi S, Montanari N, Navines J, Neumann UP, Peddu P, Primrose JN, Qu X, Raptis D, Ratti F, Ridouani F, Rogan C, Ronellenfitsch U, Ryan S, Sallemi C, Moragues JS, Sandström P, Sarriá L, Schnitzbauer A, Serenari M, Serrablo A, Smits MLJ, Sparrelid E, Spüntrup E, Stavrou GA, Sutcliffe RP, Tancredi I, Tasse JC, Udupa V, Valenti D, Fundora Y, Vogl TJ, Wang X, White SA, Wohlgemuth WA, Yu D, Zijlstra IAJ, Binkert CA, Bemelmans MHA, van der Leij C, Schadde E, van Dam RM. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy. CardioVascular And Interventional Radiology 2022, 45: 1391-1398. PMID: 35790566, PMCID: PMC9458562, DOI: 10.1007/s00270-022-03176-1.Peer-Reviewed Original ResearchConceptsFuture liver remnant hypertrophyHepatic vein embolizationMulticenter prospective single-arm trialResectable colorectal cancer liver metastasesColorectal cancer liver metastasesProspective single-arm trialFeasibility of resectionCancer liver metastasesDisease-free survivalSingle-arm trialSmall FLRPrimary endpointSecondary endpointsFLR hypertrophyLiver metastasesOverall survivalProspective trialVein embolizationLiver functionSafety profileArm trialLiver volumeWeek 1Week 3Study centers
2019
Balloon-Assisted Transarterial Chemoembolization Segmentectomy: An Alternative Strategy in the Treatment of Hypovascular Oligometastatic Liver Metastases
Stein SI, Madoff DC. Balloon-Assisted Transarterial Chemoembolization Segmentectomy: An Alternative Strategy in the Treatment of Hypovascular Oligometastatic Liver Metastases. Journal Of Vascular And Interventional Radiology 2019, 30: 1143-1145. PMID: 31126788, DOI: 10.1016/j.jvir.2018.12.704.Peer-Reviewed Original Research
2017
Portal Vein Embolization in the Treatment of Metastatic Colorectal Cancer: Optimal Approach and Current Controversies
Gans D, Siegel C, Patel I, Tavri S, Madoff D, Sutter C. Portal Vein Embolization in the Treatment of Metastatic Colorectal Cancer: Optimal Approach and Current Controversies. Digestive Disease Interventions 2017, 01: 171-183. DOI: 10.1055/s-0037-1606204.Peer-Reviewed Original ResearchPreoperative portal vein embolizationMetastatic colorectal cancerPortal vein embolizationPortal vein ligationSurgical alternativeSurgical resectionVein embolizationVein ligationColorectal cancerResectable metastatic colorectal cancerColorectal carcinoma metastaticNew surgical alternativeResidual liver volumeSubsequent surgical resectionTreatment of patientsLiver volume measurementCurrent controversiesCarcinoma metastaticLiver metastasesMetastatic diseaseLobe hypertrophyPatient selectionProper liver functionLiver functionLiver partition
2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albuminHigh Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome
Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. Journal Of Clinical Oncology 2011, 29: 1083-1090. PMID: 21263087, PMCID: PMC3068054, DOI: 10.1200/jco.2010.32.6132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChemotherapy, AdjuvantColorectal NeoplasmsFemaleHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyPatient SelectionRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTexasTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsAdvanced colorectal liver metastasesTwo-stage resectionColorectal liver metastasesLiver metastasesComplete resectionSurvival rateMedical groupMajor postoperative complicationsSurvival of patientsChemotherapy initiationNonsurgical patientsOnly chemotherapyPostoperative complicationsColorectal metastasesMetastatic diseaseObjective responseWorse survivalTreat analysisGood respondersExcellent outcomesTSR groupInclusion criteriaResectionPatientsChemotherapy
2010
Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma
Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma. Cancer Investigation 2010, 29: 49-55. PMID: 21166498, DOI: 10.3109/07357907.2010.535052.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationOverall survivalCutaneous melanoma metastaticExtrahepatic metastatic sitesHepatic arterial chemoembolizationMedian overall survivalLactate dehydrogenase levelsType of treatmentMelanoma metastaticRadiologic responseDisease stabilizationLiver metastasesMost patientsPatient ageArterial chemoembolizationPrognostic factorsLiver diseaseMetastatic sitesCutaneous melanomaMedical recordsDehydrogenase levelsPatientsSignificant predictorsChemoembolizationSurvivalExploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases
Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. Clinical Colorectal Cancer 2010, 9: 311-314. PMID: 21208846, PMCID: PMC3088086, DOI: 10.3816/ccc.2010.n.045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDrug Resistance, NeoplasmFemaleFluorouracilHepatic ArteryHumansInfusions, Intra-ArterialLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsOvarian NeoplasmsOxaliplatinPilot ProjectsSalvage TherapySurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsExtensive liver metastasesRefractory solid tumorsLiver metastasesTotal bilirubinSolid tumorsBaseline serum total bilirubinHepatic arterial infusion (HAI) oxaliplatinMedian Child-Pugh scoreAdvanced refractory malignanciesGrade 1 fatigueMedian total bilirubinRegional hepatic therapySystemic anticancer agentsChild-Pugh scoreCommon side effectsSerum total bilirubinPilot clinical trialElevated bilirubinLiver involvementPartial responseHepatic insufficiencyMedian ageRefractory malignanciesClinical trialsDisease progression
2009
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. American Journal Of Clinical Oncology 2009, 32: 574-581. PMID: 19636238, DOI: 10.1097/coc.0b013e31819cca35.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmEmbolization, TherapeuticFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHepatic ArteryHumansImatinib MesylateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPiperazinesPrognosisProtein-Tyrosine KinasesPyrimidinesRetrospective StudiesSurvival RateTreatment OutcomeConceptsImatinib-resistant gastrointestinal stromal tumorsGastrointestinal stromal tumorsProgressive liver metastasesHepatic arterial embolizationResponse Evaluation CriteriaOverall survival rateStromal tumorsArterial embolizationLiver metastasesSurvival rateRadiologic responseStable diseaseExtrahepatic metastasesPartial responseSurvival timeMedian progression-free survival timeSolid tumorsProgression-free survival ratesMedian overall survival timeProgression-free survival timeResponse criteriaCox proportional hazards modelAppreciable survival benefitEfficacy of embolotherapyProgression-free survival
2008
Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases
Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases. Annals Of Surgical Oncology 2008, 15: 2765. PMID: 18636296, PMCID: PMC5901734, DOI: 10.1245/s10434-008-0035-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsEmbolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsLiver RegenerationMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinPortal VeinPrognosisProspective StudiesSurvival RateTreatment OutcomeConceptsPortal vein embolizationColorectal liver metastasesVascular endothelial growth factorLiver metastasesLiver regenerationPreoperative chemotherapyFLR hypertrophyLiver resectionVein embolizationFuture liver remnant volumeFLR volume increaseMajor liver resectionLiver remnant volumeEffect of chemotherapyImpairs liver regenerationEndothelial growth factorConclusionPreoperative chemotherapyConcurrent bevacizumabProspective databaseRight hepatectomyPostoperative outcomesConsecutive patientsRemnant volumeBevacizumabMurine modelStrategies for Resection Using Portal Vein Embolization: Metastatic Liver Cancer
de Baere T, Madoff D, de Baere T, Elias D, Goere D, Kohneh-Sahrhi N. Strategies for Resection Using Portal Vein Embolization: Metastatic Liver Cancer. Seminars In Interventional Radiology 2008, 25: 123-131. PMID: 21326553, PMCID: PMC3036476, DOI: 10.1055/s-2008-1076680.Peer-Reviewed Original ResearchPortal vein embolizationFuture remnant liverMetastatic liver cancerLiver metastasesVein embolizationLiver cancerUse of PVEMultiple bilateral liver metastasesBilateral liver metastasesVolume of parenchymaPostoperative morbidityLiver resectionOncological conceptLiver hypertrophyRemnant liverPreoperative hypertrophyIndividual patientsTherapeutic strategiesFunctional assessmentResectionOncological landscapeThermal ablationEmbolizationPatientsMetastasis
2007
Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases
Kamat PP, Gupta S, Ensor JE, Murthy R, Ahrar K, Madoff DC, Wallace MJ, Hicks ME. Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases. CardioVascular And Interventional Radiology 2007, 31: 299-307. PMID: 17922160, DOI: 10.1007/s00270-007-9186-3.Peer-Reviewed Original ResearchConceptsProgression-free survivalHepatic arterial embolizationGastrointestinal stromal tumorsOverall survivalNeuroendocrine tumorsRadiologic responseArterial embolizationDisease stabilizationLiver involvementLiver metastasesMajor complicationsLonger progression-free survivalLiver tumor burdenMedian overall survivalMetastatic neuroendocrine tumorsProcedure-related mortalityMajority of patientsManagement of patientsAdditional risk factorsHigh response rateStable diseaseSymptom palliationPartial responsePerformance statusProgressive diseaseSystemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival
Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. Journal Of Gastrointestinal Surgery 2007, 11: 1498-1505. PMID: 17849166, DOI: 10.1007/s11605-007-0272-2.Peer-Reviewed Original ResearchConceptsBilateral colorectal liver metastasesColorectal liver metastasesPreoperative portal vein embolizationTwo-stage hepatectomyGroup IGroup IISystemic chemotherapyLiver metastasesSurvival rateDisease-free survival ratesBackgroundTwo-stage hepatectomyDay postoperative mortalityOne-stage hepatectomyPreoperative systemic chemotherapyGroup II patientsMedian hospital stayOutcomes of patientsPortal vein embolizationTreatment of patientsSecond-stage hepatectomyPostoperative mortalityAggressive surgeryBilateral diseaseHospital stayMajor hepatectomyPilot study of regional, hepatic intra‐arterial paclitaxel in patients with breast carcinoma metastatic to the liver
Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G. Pilot study of regional, hepatic intra‐arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer 2007, 109: 2190-2196. PMID: 17464952, DOI: 10.1002/cncr.22672.Peer-Reviewed Original ResearchConceptsDominant liver metastasisBreast carcinomaTaxane exposureLiver metastasesAntitumor activityCommon treatment-related toxicitiesHepatic intra-arterial therapyPatient underwent liver resectionCourses of paclitaxelUnderwent liver resectionMean patient ageTreatment-related toxicityHepatic arterial infusionIntra-arterial therapyProcedure-related complicationsBreast carcinoma metastaticMetastatic breast carcinomaIntra-arterial catheterPercutaneous transfemoral approachTime of treatmentHepatic infusionStable diseaseCarcinoma metastaticPaclitaxel therapyTaxane therapy
2006
Pilot study of regional hepatic intra-arterial (HIA) paclitaxel in patients (Pts) with breast carcinoma metastatic to the liver
Mavligit G, Kurzrock R, Cheung A, Gupta S, Madoff D, Wallace M, Kim E, Curley S, Hortobagyi G, Camacho L. Pilot study of regional hepatic intra-arterial (HIA) paclitaxel in patients (Pts) with breast carcinoma metastatic to the liver. Journal Of Clinical Oncology 2006, 24: 10626-10626. DOI: 10.1200/jco.2006.24.18_suppl.10626.Peer-Reviewed Original ResearchAnti-tumor activityBreast carcinomaTaxane exposureDominant liver metastasisHepatic arterial therapyPrevious treatment regimensUnderwent liver resectionMean hospital stayBreast carcinoma metastaticMetastatic breast carcinomaIntra-arterial catheterPercutaneous transfemoral approachGood anti-tumor activityMost common treatmentTime of treatmentAdjuvant regimensArterial therapyCarcinoma metastaticDisease stabilizationHospital stayPaclitaxel therapyTaxane therapyLiver involvementLiver metastasesLiver resectionYttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer
Murthy R, Oh Y, Tam A, Gupta S, Madoff D, Glisson B. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Journal Of Clinical Oncology 2006, 24: 17122-17122. DOI: 10.1200/jco.2006.24.18_suppl.17122.Peer-Reviewed Original ResearchHepatic metastasesSIR-SpheresLung cancerLiver metastasesSystemic therapyAdvanced liver metastasesLiver-dominant metastasesPrimary lung malignancyRegional hepatic therapyUnresectable hepatic metastasesColorectal liver metastasesLocal disease controlMetastatic lung cancerYttrium-90 Microsphere TreatmentMajority of patientsProgression of diseaseGr. 1Dominant metastasesStable diseaseVisceral arteriographyMedian doseSystemic chemotherapyArterial embolizationLine therapyMedian interval